Home » News » Research News » New Study Compares Bipolar Medications


New Study Compares Bipolar Medications

By Senior News Editor
Reviewed by John M. Grohol, Psy.D. on January 19, 2011

New Study Compares Bipolar Medications A new federal grant is fueling a new study of the effectiveness of medications used to treat bipolar disorder.

In the study, Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, along with the Bipolar Trials Network, will launch Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness).

The 10-site nationwide trial will evaluate the real-world advantages and disadvantages of quetiapine, a widely prescribed second-generation antipsychotic mood-stabilizing medication (brand name Seroquel), compared to lithium, the gold standard mood stabilizer, for the treatment of outpatients with bipolar disorder.

Bipolar disorder is a lifelong, chronic and highly recurrent mood disorder characterized by episodes of mania or hypomania that alternate with episodes of major depression. The illness creates a great deal of human suffering, which places the disorder among the top 10 causes of disability worldwide with associated costs of $70.6 billion per year for treatment and prevention.

“Studies that compare treatments for bipolar disorder usually don’t allow participants to take other medications and most patients need several medications to feel and stay well,” said Joseph R. Calabrese, M.D., of Case Western.

“Bipolar CHOICE is unique because participants can be treated, not only with quetiapine or lithium, but with almost any other medication excluding other antipsychotics.”

Over the past 10 years, the pharmacologic treatments for bipolar disorder have shifted away from lithium, which is available as a generic medication in favor of newly developed antipsychotics, such as quetiapine. Both drugs have well documented side effects.

Quetiapine has the risk of drowsiness, weight gain, and increases the risk of cardiovascular disease. Lithium is associated with the risk of long-term thyroid and kidney problems.

Calabrese believes that this study distinguishes itself as having the potential of making a real pragmatic contribution to the treatment of patients with bipolar disorder.

“Future trials need to focus on effectiveness, not just on whether one treatment appears better than placebo<” he said. ”We need studies that inform the day-to-day practice of psychiatry in a meaningful way. With real world studies in psychiatry viewed as being unusual, this study has the potential of doing just that.”

The AHRQ grant is part of an investments made under the American Recovery and Reinvestment Act of 2009 which designated $1.1. billion to support patient-centered outcomes research. This research is designed to inform health care decisions by providing evidence and information on the effectiveness, benefits and harms of different treatment options.

Ten grants totaling $100 million were awarded across the country, and this particular grant was the only one awarded to study mental illness.

The study is funded by a $600,000 grant to Case Western Reserve University School of Medicine from the Agency for Healthcare Research Quality. The trial began enrolling patients January 11.

Source: Case Western Reserve University

 

APA Reference
Nauert, R. (2011). New Study Compares Bipolar Medications. Psych Central. Retrieved on October 22, 2014, from http://psychcentral.com/news/2011/01/18/new-study-compares-bipolar-medications/22735.html